Put companies on watchlist
Pentixapharm Holding AG
ISIN: DE000A40AEG0
WKN: A40AEG
Curious about what AI knows about Pentixapharm? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Pentixapharm Holding AG · ISIN: DE000A40AEG0 · EQS - Company News (21 News)
Country: Germany · Primary market: Germany · EQS NID: 2117758
15 April 2025 08:17AM

Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year


EQS-News: Pentixapharm Holding AG / Key word(s): Annual Report/Annual Results
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year

15.04.2025 / 08:17 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, April 15, 2025 – The Management Board and Supervisory Board of Pentixapharm Holding AG today announced the following key resolutions:

  • The Group closed the 2024 financial year with a net loss of EUR 12.8 million, as reflected in the newly published annual financial statements.
  • Based on current planning, the Company expects a net loss of approximately EUR 23.5 million for the 2025 financial year.

This forecast reflects expected research and development expenses of around EUR 11 million and personnel and other operating expenses of around EUR 9.5 million. Potential revenues from out-licensing activities are not included in the forecast.

The full Annual Report for the 2024 financial year was published today, on April 15, 2025. The Company will host an investor call to present the financial results at 2:00 p.m. CEST on the same day. Registration is available at the following link:

Link to registration


About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.

 

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
ir@pentixapharm.com
Tel. +49 30 94893232
www.pentixapharm.com



15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2117758

 
End of News EQS News Service

2117758  15.04.2025 CET/CEST

Visual performance / price development - Pentixapharm Holding AG
Smart analysis and research tools can be found here.
MIC: XETR
Power-Shortcuts

Pentixapharm Holding AG

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.